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China
Brain ischemic preconditioning (PC) provides vital insights into the endogenous
protection against stroke. Genomic and epigenetic responses to PC condition the
brain into a state of ischemic tolerance. Notably, PC induces the elevation of histone
acetylation, consistent with evidence that histone deacetylase (HDAC) inhibitors protect
the brain from ischemic injury. However, less is known about the specific roles of HDACs
in this process. HDAC3 has been implicated in several neurodegenerative conditions.
Deletion of HDAC3 confers protection against neurotoxicity and neuronal injury. Here,
we hypothesized that inhibition of HDAC3 may contribute to the neuronal survival
elicited by PC. To address this notion, PC and transient middle cerebral artery occlusion
(MCAO) were conducted in Sprague-Dawley rats. Additionally, primary cultured cortical
neurons were used to identify the modulators and effectors of HDAC3 involved in PC.
We found that nuclear localization of HDAC3 was significantly reduced following PC
in vivo and in vitro. Treatment with the HDAC3-specific inhibitor, RGFP966, mimicked
the neuroprotective effects of PC 24 h and 7 days after MCAO, causing a reduced
infarct volume and less Fluoro-Jade C staining. Improved functional outcomes were
observed in the neurological score and rotarod test. We further showed that attenuated
recruitment of HDAC3 to promoter regions following PC potentiates transcriptional
initiation of genes including Hspa1a, Bcl2l1, and Prdx2, which may underlie the
mechanism of protection. In addition, PC-activated calpains were implicated in the
cleavage of HDAC3. Pretreatment with calpeptin blockaded the attenuated nuclear
distribution of HDAC3 and the protective effect of PC in vivo. Collectively, these results
demonstrate that the inhibition of HDAC3 preconditions the brain against ischemic
insults, indicating a new approach to evoke endogenous protection against stroke.
Keywords: preconditioning (PC), HDAC3, MCAO, RGFP966, calpain
Abbreviations: ChIP, chromatin immunoprecipetition; DIV, days in vitro; HAT, histone transacetylase; HDAC, histone
deacetylase; MCAO, middle cerebral artery occlusion; MTT, 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide;
OGD/R, oxygen-glucose deprivation and reoxygenation and restored energy supply; PC, preconditioning; TTC, 2,3,5-
Triphenyltetrazolium chloride.
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INTRODUCTION
Brain ischemia, induced by transient or permanent interruption
of the blood supply, is a major cause of mortality and
morbidity worldwide (Johnston et al., 2009; Feigin et al., 2014).
The mechanisms of neuronal death in stroke are complex;
involving cell membrane depolarization, free radical generation,
excitotoxicity, and neuroinflammation (Dirnagl et al., 1999;
Moskowitz et al., 2010). Despite extensive efforts, therapeutic
strategies focusing on the pathological signaling cascades have
not been successful (Moretti et al., 2015). Effective treatments
for ischemic brain damage remain one of the major unfulfilled
medical needs of clinical care (Fisher and Saver, 2015). Ischemic
PC is an approach in which a sub-lethal ischemic exposure
evokes endogenous protection against a subsequent, more
severe ischemic insult. Not only can this therapy be applied
in individuals, induced ischemic tolerance is also a strategy
to obtain insights into neuroprotective mechanisms (Dirnagl
et al., 2009; Stevens et al., 2014). PC stimuli may be identified
by diverse sensors and transducers, and consequently initiate
protection such as temporal gene profiles resistant to typically
lethal ischemic insults by effectors.
Different genomic profiles and epigenetic reprogramming
of the brain have been reported between ischemic PC and
ischemic injury (Stenzel-Poore et al., 2003; Thompson et al.,
2013). Thereby identification of epigenetic determinants of PC is
the key for pharmacological manipulation to evoke conditioning.
In vivo studies have shown that pan-HDAC inhibitors protected
the brain from ischemic injury, by elevating the severe decrease of
histone acetylation (Chuang et al., 2009; Langley et al., 2009). The
treatment of myocardial ischemia with HDAC inhibitors triggers
the PC effects against ischemia/reperfusion injury. Likewise,
studies in retina and brain ischemia revealed an elevation
of histone acetylation following PC, which may be associated
with regulation of the deacetylase activity of HDAC or HAT
recruitment (Yildirim et al., 2014; Fan et al., 2016). These studies
have raised the hypotheses that HDACs might converge in
the conditioning signaling pathways. However, considering the
significant effects of HDAC inhibitors against ischemia, less is
known about the specific role of HDACs in brain PC.
HDAC3, a homologue of Rpd3 from budding yeast, has been
linked to neurotoxicity in several neuropathological conditions
(Butler and Bates, 2006; Yang and Seto, 2008). In Caenorhabditis
elegans knock-down of the homolog of HDAC3, HDA-3,
suppressed Htn-Q150 toxicity in a model of Huntington’s
disease (Bates et al., 2006). In rat cerebellar granule neurons,
mutant Htt disrupted the sequestration of HDAC3 and the
liberation of HDAC3 resulted in neurotoxic activity (Bardai et al.,
2013). Additionally, suppression by HDAC3 shRNA protected
cerebellar granule neurons against a low-potassium insult, while
overexpression of HDAC3 promoted the death of neurons
(Bardai and D’Mello, 2011). Conditional knock-out of Hdac3
in retinal ganglion cells displayed a significant amelioration of
nuclear atrophy and reduction in cell death induced by optic
nerve injury (Schmitt et al., 2014).
Given the properties of HDAC3 in neurodegeneration, we
speculate whether inhibition of HDAC3 contributes to the
neuronal survival elicited by PC. We first investigated histone
acetylation and class I HDAC subcellular localization following
PC. We found that PC-induced acetyl-histone 3 Lysine 9
(H3K9ac) elevation was accompanied by reduced HDAC3
nuclear localization in cortical neurons. Based on this, efficient
and specific pharmacological inhibition of HDAC3 in vivo
and knock-down of HDAC3 in vitro in models of ischemia
were performed. The results showed that specific inhibition of
HDAC3 could precondition the brain against ischemic injury
24 h and 7 days after MCAO in vivo, via the initiation of
a gene-expressing program associated with neuroprotection.
Furthermore, we identified that calpains were implicated in the
cleavage of HDAC3, which blocked the nuclear distribution of
HDAC3. Overall, the results demonstrate the importance of
HDAC3 in the process of PC, providing a new pharmacological
approach to evoke protection due to ischemic conditioning.
MATERIALS AND METHODS
Animals
Adult male Sprague-Dawley rats weighing 250–280 g were used
in this study (Laboratory Animal Center, Chinese Academy of
Sciences, Shanghai, China). All experimental procedures were
performed in accordance with the Guide for the Care and Use of
Laboratory Animals (National Institutes of Health) and approved
by the Institutional Animal Care and Use Committee of Shanghai
Institute of Materia Medica.
MCAO and Ischemic Preconditioning
All animals were acclimatized for 2 weeks before pharmacological
treatment or surgery. The induction of transient focal cerebral
ischemia was performed as previously described (Longa et al.,
1989), with minor modifications. Briefly, the animals were
anesthetized with chloral hydrate (400 mg/kg, i.p.). A 4-0
monofilament nylon surgical suture (Sunbio Biotech Co. Ltd.,
Beijing, China) with a rounded tip was introduced through
the external carotid artery to the internal carotid artery and
advanced up to 18–20 mm to block the middle cerebral artery.
After a period of occlusion, 5 min for ischemic PC and
90 min for injurious ischemia, the suture was withdrawn to
allow reperfusion. Regional cerebral blood flow was monitored
throughout surgery using a laser Doppler (moorVMS-LDF2,
Axminster, UK) to exclude rats that showed a cerebral blood
flow (CBF) reduction of less than 80%. Rectal temperature was
monitored and the core body temperature was maintained at
37 ± 0.5◦C by a feed-back-controlled heat pad (Hugo Sachs
Elektronik, March-Hugstetten, Germany). Rats were transferred
back to their cages after recovery from anesthesia and rested
in home cages before sacrifice. Sham operation were conducted
using an identical procedure but without the insertion of a
filament.
Experimental Design
Rats were randomly grouped (n= 8–14 per group) and subjected
to different MCAO and pharmaceutical treatments as follows
(Supplementary Figures S2A,B):
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Sham group: Sham surgery was performed on day 1 and at the
same time on day 2. Rats received vehicle injections at the same
time as the RGFP966 group or the calpeptin group below.
MCAO group: Rats underwent sham operation on day 1 and
90 min of MCAO on day 2. Rats received vehicle injections at
the same time as RGFP966 group or calpeptin group below.
PC group: Rats were subjected to 5 min of MCAO to induce
ischemic PC on day 1, and 90 min of MCAO on day 2.
RGFP966 group: Rats were treated with RGFP966 (7.5 mg/kg,
i.p) when subjected to a sham operation. The second RGFP966
was injected 6 h prior to the MCAO of 90 min on day 2.
Calpeptin group: Rats were treated with calpeptin (125 µg/kg,
i.p) 6 h before surgery, and then underwent the same
procedure as the PC group.
Rats were sacrificed 24 h or 7 days after injurious MCAO.
Pharmacological Treatment
Drugs were administrated at a volume of 5 ml/kg. RGFP966
(S7229, Selleckchem, Houston, TX, USA) was dissolved in
DMSO, and diluted in a vehicle of 100 mM sodium acetate
(PH 5.4) and 30% (wt/vol) hydroxypropyl-beta-cyclodextrin,
with the final DMSO less than 10% (vol/vol). Calpeptin (C8999,
Sigma–Aldrich, St Louis, MO, USA) was dissolved in DMSO and
diluted in saline. Vehicles were obtained by identical procedures
without drugs. The doses were determined based on pervious
report to obtain proper concentrations in the brain (Malvaez
et al., 2013; Samantaray et al., 2015).
Infarct Volume Quantification
The cerebral infract volumes were measured using TTC
(T8877, Sigma–Aldrich) staining. Rat brains were harvested
and sectioned into 2 mm thick coronal sections 24 h or
7 days after MCAO. Then sections were stained with 1%
TTC at 37 ◦C for 5 min, and fixed in 4% paraformaldehyde
(PFA) solution for 48 h. The images were captured and
analyzed using Image-Pro Plus 7.0 (Media Cybernetics, Silver
Spring, MD, USA). The infarct volume (%) for the brain
was calculated with the following formula: (the volume of
the contralateral hemisphere – the volume of the non-
lesioned ipsilateral hemisphere)/(the volume of the contralateral
hemisphere× 2). The ipsilateral hemisphere underwent occlusive
treatment in the MCA, while the contralateral hemisphere
did not. Investigators were kept blind to the treatment
assignments.
Neurological Function Analysis
The neurological deficits score after surgery was evaluated
according to validated scoring analyses with minor modifications
(Longa et al., 1989): 0, no observable deficit; 1, unable to fully
stretch the forelimb of the right side (the left MCA was occluded
in this study); 2, decreased resistance to lateral push, circling
to the right side but normal gesture at rest; 3, unilateral rolling
to the right side; 4, occasionally leaning to the right side,
declined locomotor activity; 5, unable to sustain normal gesture
at rest, unresponsive. Investigators were kept blind to treatment
assignments.
Rotarod Test
Rats were trained and tested on rotarod (IITC Life Science,
Woodland Hills, CA, USA) which gradually accelerated from 4
to 40 rpm over 5 min (Hunter et al., 2000). The latency to fall
was recorded as the time before rats fell off the rod or gripped
and spun around for two successive revolutions. Rats underwent
three training trails a day for 3 days. The base line control was
recorded 1 day before the surgery. The mean latency was obtained
from 3 trials with 30 min interval on the testing day. Investigators
were kept blind to treatment assignments.
Primary Culture of Rat Cortical Neurons
and Treatment
Primary cortical neurons were prepared from embryonic E17
Sprague-Dawley rats and cultured with Neurobasal medium and
B27 supplement (Thermo Fisher Scientific, USA) as described
previously (Xie et al., 2009). Neurons were cultured at 37◦C
in a humidified 5% CO2 atmosphere and the medium was
replaced by fresh every 3 days. Neurons at 7 DIV were used
for experimentation. In the OGD treatment, the glucose-free
Dulbecco’s Modified Eagle Medium (DMEM) (Thermo Fisher
Scientific) was bubbled with 95% N2/5% CO2. The chamber was
pre-warmed, humidified, and flushed with 95% N2/5% CO2 at
3 liter/min for 5 min. The oxygen content was under 0.50%
(v/v) throughout the experimental period detected with oxygen
monitor (Jiande Analytical Instrument, Hangzhou, China). For
PC treatment, the culture medium was replaced with and cells
were placed glucose-free DMEM in an experimental hypoxia
chamber for 45 min for neurons or 1.5 h for PC12. The cells
were then removed from the chamber and cultured under normal
conditions for the indicated periods (see figure legends). For the
OGD/R model, neurons were cultured in glucose-free DMEM in
a hypoxia chamber for 90 min and returned to normal culture
conditions for 24 h. The control cells were cultured in a medium
with glucose in a normal oxygen-condition incubator for the
same time periods.
Tissue Preparation
After anesthetization, brains were immediately removed. Brain
tissue were obtained by coronal sectioning and harvested along
the core region of occlusion underlying the middle cerebral
artery. The tissues were immediately frozen in liquid nitrogen,
and stored at−80◦C.
Western Blot
The brain tissue or cultured cells were lysed in a RIPA
buffer with proteinase and phosphatase inhibitor cocktail
(Sigma–Aldrich) for whole cell protein. The nuclear and
cytoplasmic fractions were extracted with NE-PER Nuclear
and Cytoplasmic Extraction Reagents Kit (Pierce, Rockford,
IL, USA) following the manufacturer’s instruction. The protein
concentration was quantified using a BCA assay kit (Thermo
Fisher Scientific). Samples were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and
transferred to PVDF membranes (Merck-Millipore, Bedford,
MA, USA). Blots were then probed with specific antibodies:
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anti-H3K9ac (ab12179, Abcam, Cambridge, MA, USA), anti-
HDAC1 (WH0003065M2, Sigma–Aldrich), anti-HDAC2
(ab16032, Abcam), anti-HDAC3 (ab47237, Abcam), anti-lamin
A/C (2032, Cell Signaling Technology, Beverly, MA, USA),
anti-β-actin (A8481, Sigma–Aldrich), anti-Bcl-xL (2764, Cell
Signaling Technology), anti-Prdx2 (10545-2-AP, Proteintech
Group, Chicago, IL, USA), anti-HSP70 (sc-32239, Santa Cruz,
Dallas, TX). After incubation with HRP-conjugated secondary
antibodies (Santa Cruz), chemiluminescence signals were
detected with ECL reagents (GE Health, Little Chalfont, UK).
Histological and Immunohistochemical
Assessment
After anesthesia with chloral hydrate, rats were injected
transcardially with ice-cold 4% PFA in PBS. Brains were
post-fixed in PFA for 24 h and dehydrated with 30%
(wt/vol) sucrose for 48 h. Next, 25 µm coronal slices
were obtained with a Leica freezing microtome. Primary
antibodies used in immunofluorescence staining were: anti-
H3K9ac (ab12179, Abcam), anti-HDAC3 (ab47237, Abcam) and
anti-MAP2 (ab11267, Abcam). The sections were incubated with
300 nM 4,6-diamidino-2-phenylindole (DAPI, Sigma), Alexa
Fluor 488 and Alexa Fluor 555 secondary antibodies (Thermo
Fisher Scientific) for 45 min at 25◦C. An Olympus FV1000
confocal laser scanning microscope was applied for acquisition
of fluorescence images. 3,3′-diaminobenzidine immunostaining
was performed with primary antibodies against: HSP70 (sc-
32239, Santa Cruz), following with SignalStain Boost IHC
Detection Reagent and visualized with SignalStain DAB Substrate
Kit (Cell Signaling Technology). Images were acquired using a
Leica microscope. Fluoro-Jade C (FJC) staining was performed
according to the protocol provided by the manufacturer
(Chemicon, Merck-Millipore). Images were obtained using
an Olympus FV1000 confocal microscope. For histological
quantification of H3K9ac intensity and FJC positive cells, images
were obtained from two random 20× fields of the cortical
area in three coronal sections (Interaural 10.60 mm/Bregma
1.60 mm, Interaural 9.20 mm/Bregma 0.20 mm, Interaural
7.12 mm/Bregma −1.88 mm) (Supplementary Figure S2C).
Average intensities or cell counts were calculated from 5 rats per
group with Image Pro Plus 7.0. Investigators were kept blind to
treatment assignments.
Co-immunoprecipitation (Co-IP) Assay
Cell lysates were generated by incubating cells with an NP-40
lysis buffer with proteinase inhibitor cocktail on ice and then
centrifuged at 10000 g for 10 min. Immunoprecipitation was
carried out by incubating the lysate with the corresponding
antibodies: anti-HDAC3 (ab47237, Abcam), anti-calpain1
(ab28258, Abcam), anti-calpain2 (ab39165, Abcam) and anti-HA
(3724, Cell Signaling Technology) with slow agitation overnight
at 4◦C. Next, 20 µl PureProteome Protein A/G Mix Magnetic
Beads (Merck-Millipore) was added and incubated with slow
agitation for 4 h at 4◦C. Immune complexes were washed
extensively, boiled in SDS-sample buffer and analyzed using
SDS-PAGE.
Quantitative Reverse Transcription
Polymerase Chain Reaction (qRT-PCR)
Total RNA was extracted from cortical neurons after treatment
using TRIzol reagent (Thermo Fisher Scientific). Next, 1 µg
total RNA was converted to cDNA using a reverse transcription
kit (Takara, Cat# RR047A). After the RT reaction, cDNA was
used for subsequent real time PCR (SYBR Premix Ex TaqII
Kit) following the manufacturer’s protocol. The qPCR and data
collection were carried out on ABI 7500 real-time PCR system
(Applied Biosystems, Foster City, CA, USA). The results relative
to the quantitation value for each target gene were expressed as
2−11Ct. All PCR primers are shown in Supplementary Table S1.
Chromatin Immunoprecipetition and
Real-Time PCR
Chromatin immunoprecipetition was carried out according to
the protocol of the EZ-Magna ChIP kit (17-10086, Millipore).
Briefly, the nuclear content of cortical neurons was extracted
and the chromatin inside was sonicated into fragments.
Fragmented chromatin was incubated and immunoprecipitated
using anti-H3K9ac antibody (17-609, Millipore) and anti-
HDAC3 antibody (17-10238, Millipore). After the de-crosslink,
immunoprecipitated DNA and whole-cell extract DNA were
then eluted and subjected to real-time PCR analysis using SYBR
Premix Ex TaqII Kit (Takara, Shiga, Japan). All PCR primers are
shown in Supplementary Table S2.
Plasmid Constructs and Transfection
Full-length human HDAC3 cDNA was synthesized by
GENEWIZ (South Plainfield, NJ, USA) and ligated into the
expression vector, HA-pcDNA3.0. C-terminus-truncated
construct HDAC3 mutant (1C-HDAC3, 1-312) was amplified
with primers: 5′GATATCGATGGCCAAGACCGTGGCGTATT
TC3′ and 5′CTCGAGTTAAGATGTTTCATATGTCCAGCAC
CG3′ using full length HDAC3 cDNA as the template.
Transient transfection was conducted using the FuGENE
HD transfection reagent (Promega, Madison, WI, USA)
according to the manufacturer’s instructions. siRNA-HDAC3
(s136736, Dharmacon) was transfected into cortical neurons by
the FuGENE HD transfection reagent. The silencing effect of
protein expression was confirmed by western blot analysis.
Cell Viability
Neuron viability was assessed using the MTT assay as described
previously. Briefly, MTT solution (0.5 mg/ml) was added to each
well and incubated with cells for an additional 3 h at 37◦C. The
formazan was then dissolved with DMSO and the absorbance
at 595 nm was read by a microplate reader (NOVOstar, BMG
LABTECH, Offenburg, Germany).
Statistical Analysis
Quantifications and statistical analysis were carried out using
GraphPad Prism 6 (Graphpad Software, San Diego, CA, USA).
All values are presented as means ± SEM. Differences between
groups were compared with a one-way ANOVA followed by
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group comparisons using a post hoc Bonferroni test or two-
tailed Student’s t-test. Neurological deficit scores were analyzed
using the Kruskal–Wallis non-parametric test followed by Dunn’s
multiple comparisons test.
RESULTS
Acetylation of H3K9 Increased in Cortical
Neurons in Preconditioning,
Accompanied by Reduction of Nuclear
Localization of HDAC3
Histone acetylation was shown to be differentially regulated
depending on the duration of ischemia. While injurious ischemia
led to a severe decline of histone acetylation in stroke models
(Supplementary Figure S1A) (Ren et al., 2004; Faraco et al., 2006;
Kim et al., 2007), PC for 5 min followed by 2 h reperfusion
in rats induced increased levels of acetyl-H3K9 in the cortex,
as assessed with both immunoblotting (p < 0.05, n = 5) and
immunohistochemistry (p < 0.001, n = 5) (Figure 1A). We
next measured levels of expression of the three class I HDAC
subtypes with which the deacetylation of histone lysine residuals
is largely associated. Western blot assay on nuclear lysates
revealed that the levels of HDAC3, but not HDAC1 or HDAC2,
were reduced in the nuclei following PC (p < 0.05, n = 4–6)
(Figure 1B). To further determine the involvement of HDAC3
in PC, the subcellular localization of HDAC3 was assessed
with immunofluorescence. The results showed that HDAC3
was distributed both in the nucleus and cytoplasm in cortical
neurons before PC, while it was localized mainly in the cytoplasm
following PC treatment (Figure 1C). Meanwhile, the modulation
of histone acetylation (Figure 1D) and the nuclear reduction
of HDAC3 following PC were verified with primary cortical
neuron cultures (Figure 1E, Supplementary Figures S1C,D).
These results indicated that a diminished recruitment of HDAC3
to the genomic arena might contribute to the modulation of the
histone acetylation profile following PC.
Inhibition of HDAC3 Mimicked the
Neuroprotective Effects of PC In vivo
Given the changes in redistribution of HDAC3 following
PC, we wondered whether inhibition of HDAC3 mimics the
neuroprotective effect of PC. Rats with different treatments were
subjected to MCAO (Supplementary Figure S2A). RGFP966, a
known HDAC3-specific inhibitor, was injected 24 and 6 h prior
to MCAO. The RGFP966-treated group exhibited significantly
reduced infarct volume compared with the vehicle-treated group
24 h (7.68 ± 2.90% versus 19.09 ± 2.91%, p < 0.05, n = 7–9)
and 7 days (8.62 ± 2.00% versus 18.25 ± 3.75%, p < 0.05,
n = 8–10) after reperfusion. Furthermore, the anterior-posterior
analysis of infarct distribution revealed that the infarction
mostly occupied the striatum and temporal cortex, which was
decreased in slices 2, 3, 4 in the PC and RGFP966 group
(Figures 2A,B). Brain coronal sections obtained 24 h and
7 days after MCAO were stained with FJC to label degenerating
neurons (Figures 2C,D). Higher levels of FJC staining were
observed in the MCAO group compared to with the Sham
group, and significantly decreased labeling with FJC in the
RGFP966-treated group compared with the MCAO group in
both 24 h and 7 days assessments (n = 5). Furthermore,
we analyzed the counterstain of FJC with GFAP or Iba with
brain sections obtained 24 h after MCAO. The schematic
brain section and outlined box showed the area where images
were acquired in the ipsilateral hemisphere (Supplementary
Figure S5A). Activated astrocytes and microglia were observed
in MCAO group, while less activation in PC and RGFP966
group (Supplementary Figures S5B,C). Meanwhile, neurological
function was evaluated using the neurological deficit score
and rotarod test. Rats treated with RGFP966 displayed lower
neurological deficit scores (n = 8–10) and improved rotarod
performance (n = 8–10) throughout 7-day test compared with
the Sham group (Figures 2E,F).
Attenuated Recruitment of HDAC3 to
Promoter Regions Following PC
Potentiated Transcriptional Initiation of
Oxidation Relative Genes
Concomitant with the data in vivo, the reduction in cell
viability elicited by OGD/R was blocked by both RGFP966
pretreatment and HDAC3 knock-down in primary cultured
cortical neurons, as determined by the MTT assay (Figure 3A).
To further elaborate the underlying role of HDAC3 in PC, data
mining linking HDAC3 targeting genes (Feng et al., 2011) and
ischemia was performed and determined a group of associated
genes. ChIP analysis revealed that promoter occupancy of
HDAC3 on Hspa1a, Prdx2 and Bcl2l1 were markedly reduced
in response to PC, and concomitantly H3K9 acetylation levels
were significantly elevated. Furthermore, RGFP966 pretreatment
or HDAC3 knock-down also induced increases in H3K9
acetylation near the HDAC3 binding sites of indicated genes
(Figures 3B,C). Consistently the expression of indicated genes
increased significantly in PC, RGFP966 treatment or HDAC3
knock-down (Figure 3D). We next exposed primary neurons
to injurious OGD/R with the same procedure in Figure 3A.
Western blot analysis showed that OGD/R slightly induced
HSP70 expression, but suppressed Bcl-xL and Prdx-2 expression,
while RGFP966 treatment or HDAC3 knock-down, consistent
with PC, enhanced expression of all indicated genes compared
with OGD/R (Figure 3E, Supplementary Figure S6). Taken
together, we have demonstrated that the diminished recruitment
of HDAC3 observed in PC led to up-regulation of HDAC3 related
genes associated with neuroprotection.
Inhibition of Calpain1/Calpain2 Blocked
the Reduction of HDAC3 Nuclear
Localization Following PC
Subcellular localization of HDAC3 was shown to be controlled by
protein-protein interaction or proteolytic cleavage (Karagianni
and Wong, 2007). The unique C-terminus of HDAC3 is
essential for nuclear localization and assembly into co-repression
complexes (Yang et al., 2002). Several cleavages of HDAC3 by
different proteases, which are activated with temporal specificity
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FIGURE 1 | Preconditioning induced the elevation of acetyl-H3K9 levels and reduced HDAC3 nuclear localization in rat cortical neurons in vivo and
in vitro. Rats underwent 5 min PC treatment followed by 2 h reperfusion (A–C). (A) Acetyl-H3K9 levels in the cortex by immunoblotting (Left, n = 5) and
immunohistochemistry (Right, n = 5). ∗p < 0.05, ∗∗∗p < 0.001 Student’s t-test. Scale bar: 100 µm. (B) Quantification of class I HDAC subtypes in nuclear lysates
(n = 4–6). ∗p < 0.05, Student’s t-test. (C) Representative images of HDAC3 subcellular localization following sham or PC treatment in vivo. Scale bar: 50 µm.
(D) Primary cultured cortical neurons underwent PC for 45 min followed by reoxygenation and restored energy supply for indicated period. Levels of H3K9
acetylation were assessed with whole cell lysates. Data are mean ± SEM. ∗∗p < 0.01 versus control, ANOVA. (E) Representative images of HDAC3 subcellular
localization in rat cortical neurons after PC. Scale bar: 25 µm.
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FIGURE 2 | RGFP966 protected the brain from ischemic injury in vivo. Infarct measurements were performed 24 h (n = 7–9) (A) and 7 days (n = 8–10) (B)
after MCAO. Representative images of TTC staining (Left), infarct volume percentage (Middle) and infarct area for each slice (Right) from each group. ∗∗p < 0.01,
∗p < 0.05 versus MCAO group, ANOVA. Representative images of Fluoro-Jade C staining in each group. The histogram shows the numbers of degenerating
neurons in the cortex 24 h (C) or 7 days (D) after MCAO (over 30 slices from five rats per group). ∗∗p < 0.01, ∗∗∗p < 0.001 versus MCAO group, ANOVA. Functional
outcomes were assessed using the neurological deficits score (day 1, 4, and 7 after MCAO) (E) and rotarod test (day 4 and 7 after MCAO) (F) (n = 8–10). ∗p < 0.05,
∗∗p < 0.01 versus MCAO group, ANOVA.
in the process of cerebral ischemia, are involved in regulating
the cellular distribution of HDAC3. We pretreated neurons
with three major proteolytic pathway inhibitors including
bortezomib (proteasome inhibitor), Z-VAD-FMK (pan-caspase
inhibitor), and calpeptin (calpain inhibitor). PC was then
conducted. Immunofluorescence results showed that calpeptin
pretreatment, but not bortezomib or Z-VAD-FMK rescued
the reduction of nuclear HDAC3 (Figure 4A). Western blot
analysis with whole cell lysates showed a lower band of
HDAC3 in PC treated neurons, suggesting a cleavage of HDAC3
induced by PC (Figure 4B). Furthermore, immunoprecipitation
was performed with anti-HDAC3 or anti-calpain1/calpain2
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FIGURE 3 | Diminished recruitment of HDAC3 to the promoter region following PC potentiated the transcriptional initiation of oxidation relative
genes. (A) For non-PC groups, cortical neurons at 7 DIV were pretreated with RGFP966 (2 µM) for 2 h, or transfected with siRNA targeting HDAC3 at 5.5 DIV 36 h
in advance. For PC group, PC was induced at 6 DIV followed by reoxygenation. All groups underwent OGD/R at the same time at 7 DIV. At the end of the OGD/R
period, cell viability was assessed using an MTT assay and calculated as the percentage of the non-treatment control. ###p < 0.001 versus control; ∗∗p < 0.01,
∗∗∗p < 0.001 versus OGD/R, ANOVA. Primary cultured neurons were subjected to PC or pretreated with RGFP966 for 2 h at 7 DIV, or transfected with siRNA
targeting HDAC3 at 5.5 DIV 36 h in advance. Samples for ChIP were collected right after PC or RGFP966 and siHDAC3 treatment (B,C). For mRNA test samples
were collected 6 h after PC followed by reoxygenation (D). (B) ChIP with HDAC3 antibodies was conducted followed by qPCR analysis using primers for HDAC3
binding sites near the promoter of the indicated genes. (C) Acetylation of H3K9 near the HDAC3-targeting gene promoters were analyzed by ChIP-qPCR.
(D) RT-qPCR analysis for indicated genes. ∗p < 0.05, ∗∗p < 0.01, ∗∗∗p < 0.001 versus control, Student’s t-test and ANOVA. (E) Neurons were induced with PC,
pretreated with RGFP966 or siHDAC3 and then exposed to OGD/R (the same procedure with A). The expression of oxidative relative genes was analyzed at the
protein levels. Cell lysates were analyzed with specific antibodies. Data are presented as means ± SEM from three independent experiments. #p < 0.05, ##p < 0.01,
###p < 0.001 versus control; ∗p < 0.05, ∗∗p < 0.01 versus OGD/R, ANOVA.
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FIGURE 4 | Inhibition of calpains rescued the reduction of nuclear localization of HDAC3 following PC in neurons. (A) Primary cultured neurons were
treated with bortezomib (4 nM), Z-VAD-FMK (50 nM) or calpeptin (5 µM) for 2 h prior to PC. Immunohistochemistry was conducted after PC. HDAC3 localization
was visualized using immunofluorescence. Scale bars: 20 µm. (B) Cleavage products were analyzed by immunoblotting with an antibody against the N-terminus of
HDAC3 (ab47237, Abcam) after PC. (C) Bands of HDAC3 were obtained by immunoprecipitating calpain1 or calpain2 and immunoblotting with the anti-HDAC3
antibody. Bands of calpain1 and calpain2 were obtained by immunoprecipitating HDAC3 and immunoblotting with the anti-calpain1 and anti-calpain2 antibodies
respectively. (D) Plasmids encoding HA-tag, HA-HDAC3 WT, HA-HDAC3 1C were transfected into PC12 cells and PC was performed 36 h later. Whole cell lysates
were immunoprecipitated with anti-HA antibody after PC and immunoblotted with anti-calpain1 or anti-calpain2 antibodies.
antibodies. We found that direct interactions between HDAC3
and calpain1/calpain2 were strengthened after PC (Figure 4C).
To further identify the interaction domain between HDAC3
and calpain, we constructed HA-tagged WT HDAC3 and
truncated HDAC3 (aa1-312, HDAC3 1C) plasmids. Consistent
with previous reports (Yang et al., 2002), HA-HDAC3 WT
displayed both cytoplasmic and nuclear distributions, while HA-
HDAC3 1C specifically localized in the cytoplasm of neurons
(Supplementary Figure S3). A PC12 cell line was transfected
with HDAC3 constructs and underwent PC. As expected, PC
significantly increased the interaction of HA-HDAC3 WT with
calpains, while truncated mutation, HA-HDAC3 1C, reduced
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the interaction with calpains after PC compared with control
group (Figure 4D), indicating that the interaction domain may
lie in the C-terminal region of HDAC3. From these results
we concluded that blockade of HDAC3 nuclear localization
following PC treatment resulted from the C-terminal cleavage of
HDAC3 mediated by calpain1/calpain2.
Calpeptin Blocked the Attenuated
Nuclear Localization of HDAC3 and the
Neuroprotective Effect of PC In vivo
Rats were treated with calpeptin 6 h prior to surgery. To
determine the subcellular localization of HDAC3, brain sections
were obtained 2 h after PC. Immunofluorescence results
showed that calpeptin pretreatment blocked the reduction of
nuclear HDAC3 induced by PC (Figure 5A). For pathological
assessment, rats subjected to MCAO were sacrificed 24 h
or 7 d later (Supplementary Figure S2B). TTC staining
(Figure 5B) and FJC immunoreactivity (Figure 5C) revealed
that calpeptin had significantly attenuated the protective effect
of PC 24 h after MCAO, consistent with results observed
7 days after MCAO (Supplementary Figure S4). Activated
astrocytes and microglia were observed in MCAO and calpeptin
group compared with PC group (Supplementary Figures
S5D,E). Furthermore, we compared the expression level of
indicated genes in all experimental groups, including the
RGFP966 treatment group. Specimens were obtained 24 h
after MCAO. Consistent with results in vitro, the levels
of Prdx-2, Bcl-xL and HSP70 were significantly elevated in
PC and RGFP966 groups compared with the MCAO group,
while pretreatment with calpeptin attenuated the expression
enhancement of PC (Figure 5D). HSP70 regulation was further
assessed by immunohistochemistry, which revealed that HSP70
expression was enhanced by PC and RGFP966 treatment,
whereas its expression was blocked by calpeptin pretreatment
(Figure 5E).
DISCUSSION
Ischemic PC has been studied in order to develop new therapeutic
approaches to benefit patients with stroke (Dirnagl et al.,
2003; Gidday, 2006; Stetler et al., 2014). The present study
provides evidence that HDAC3 inhibition may have a role in
PC the brain against ischemia. We found that the reduction of
HDAC3 nuclear localization following PC resulted in elevated
acetylation of H3K9. Acting as one of the leading causes of
PC, release of the HDAC3 co-repressor complex facilitated the
transcription of relevant genes including Hspa1a, Bcl2l1, and
Prdx2, which contributed to the endogenous protection elicited
by PC. Further, we showed that C-terminal cleavage of HDAC3
by calpain underlies the failure of HDAC3 nuclear localization,
and inhibition of calpain attenuated the PC protection exerted by
HDAC3 inhibition.
There has been increasing interest in targeting epigenetic
process as potential treatment for stroke (Langley et al.,
2009; Aune et al., 2015). Several HDAC inhibitors such as
VPA (Kim et al., 2007; Wang et al., 2012b), TSA (Yildirim
et al., 2008; Wang et al., 2012a) and SAHA (Faraco et al.,
2006) have previously shown protective effects against cerebral
ischemia. Meanwhile, epigenetic modification is believed to play
a fundamental role in ischemic tolerance. Yet the precise roles
of HDACs in PC remains less clearly understood. Notably,
it has been reported that total histone-H3 acetylation was
down-regulated in cerebral ischemic injury but up-regulated
following PC both in vitro and in vivo (Yildirim et al.,
2014). Another study revealed a significant increase in retinal
acetyl histone-H3 labeling after PC but a pronounced decrease
after ischemia (Fan et al., 2016). In our study we further
illustrated the time course of histone modification in both
PC and OGD/R in vitro. Acetyl-H3K9 was elevated within
2 h following PC and returned to normal levels 6 h later
(Figure 1C), while it was decreased profoundly 12 h after
OGD followed by reoxygenation (Supplementary Figures S1A,B).
Different mechanisms underlying the opposite regulation have
been proposed. In the retina the deacetylase activity of HDAC1/2
displayed an increase in ischemia but a decrease following
PC, which was closely correlated with histone acetylation
modification (Fan et al., 2016). Whereas in the brain, a decrease
in histone H3 acetylation was observed for 6 h after MCAO,
strikingly without concomitant change in HAT or HDAC
activity, which might be associated with decreased acetyl-CoA
contents after ischemia (Faraco et al., 2006). In the brain
following PC, increased histone acetylation was reported to
result from enhanced CBP recruitment at the promoter of the
neuroprotective gene gelsolin (Yildirim et al., 2014). Here, we
reported that additional regulation is involved in this process,
whereby cleaved HDAC3 is distributed in the cytoplasm and
reducing the recruitment to targeted genes following PC, which
consequently elevated the level of acetyl-H3K9. All these finding
present a new perspective in explaining the protective role of
HDAC inhibitors that reinstatement of the decreased histone
acetylation level may exert the PC protection following ischemic
injury.
Numerous studies have identified the mechanisms of PC
against injurious ischemia. Gene profile analysis demonstrated
that PC induced an extensive down-regulation of genes
responsible for metabolic pathways and ion-channel activity,
indicating lowered cellular activity (Stenzel-Poore et al., 2003,
2007). Similar regulation is implicated in the response to
resveratrol treatment, which functions via the activation of
SIRT1 (NAD-dependent deacetylase sirtuin-1; Raval et al.,
2006; Koronowski et al., 2015). HIF-1-alpha also plays a
fundamental role in adapting the metabolism to hypoxic
conditions via transcriptional regulation (Prass et al., 2003;
Tang et al., 2006). Apart from the known effectors that
suppress energy turnover, cumulative evidence has suggested
that epigenetic modulators may be involved in PC paradigms.
The volume of ischemic tissue was reduced by the inhibition
of DNA methylation and histone acetylation, which elicited
a reprogramming of ischemic tolerance (Thompson et al.,
2013). In our study, ChIP assays have revealed that the
induction of PC, HDAC3 knock-down and HDAC3 inhibition
elevated the histone acetylation level of related gene including
Hspa1a, Bcl2l1, and Prdx2, and were further permissive to
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FIGURE 5 | Calpeptin pretreatment blocked the protective effect of PC in vivo. (A) Representative images of HDAC3 subcellular localization in cortex. Scale
bar: 50 µm. (B) Representative images of TTC staining from each group are shown. Infarct volume percentage from each slice were determined (n = 8–10).
∗p < 0.05 versus MCAO group, #p < 0.05 versus PC group, ANOVA. (C) Representative images of Fluoro-Jade C staining and the numbers of degenerating
neurons (over 30 slices from six rats per group). ∗∗∗p < 0.001 versus MCAO group, ###p < 0.001 versus PC group, ANOVA. (D) Expression levels of Prdx-2, Bcl-xL
and HSP70 in each group (n = 3–4) 24 h after MCAO. #p < 0.05, ###p < 0.001 versus Sham group; ∗p < 0.05, ∗∗p < 0.01 versus MCAO group, ANOVA. (E)
Representative images of Cerebral HSP70 immunohistochemistry. Scale bar: 50 µm. Calp, calpeptin.
transcriptional initiation. Notably, over 12-fold up-regulation of
HSP70 transcription was observed 12 h in PC, siHDAC3 and
RGFP966 treated cortical neurons 6 h after PC induction or
mimicking. It has been reported that HSP70 was induced in
the penumbra, but not core, of the ischemic region, as well as
in neurons which survive PC (Masada et al., 2001). Delaying
administration of HSP70 by 2.25 and 3 h after the onset of
ischemia significantly decreased infarct volume by 68% (Zhan
et al., 2010). Bcl-xL is required for neurite outgrowth and
potentially inhibits programmed cell death through changing the
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topology of the mitochondrial membrane (Park et al., 2015).
Peroxiredoxin, an antioxidant enzyme, protects cells from the
insults due to free radical accumulation (Finkel and Holbrook,
2000). These observations suggest that like other methods of
manipulating PC, HDAC3 inhibition triggers signaling cascades
in neurons leading to increased levels of free radical species and
superoxide clearance, inhibition of the endogenous cell apoptosis
program, and improved overall protein integrity, which shield the
brain from ischemic injury.
In our study we demonstrated that calpain-mediated
C-terminus cleavage of HDAC3 was responsible for the absence
of HDAC3 in nuclei following PC. HDAC3 is a member of the
class I HDAC family (HDAC1, HDAC2, HDAC3, and HDAC8),
which share homology with Rpd3 from budding yeast (Yang
and Seto, 2008). The unique C-terminus of HDAC3 is essential
for its deacetylase activity and nuclear localization (Yang et al.,
2002). Several ways of HDAC3 cleavage have been reported
to affect its distribution. Etoposide treatment resulted in the
cleavage of HDAC3 by caspase-3 and its subsequent cytoplasmic
accumulation (Choi et al., 2015). Following treatment with FasL
or ultraviolet irradiation, HDAC3 was cleaved in an indirect
caspase-dependent manner and subsequently distributed in the
cytoplasm (Escaffit et al., 2007). In the present study, minimum
amount of interaction between HDAC3 and calpains were
observed under normal conditions. While following PC and
pretreatment with different protease inhibitors, we confirmed
HDAC3 was cleaved by calpains, but not caspase or proteasome.
From our results we cannot determine the difference in cleavage
participation between calpain1 and calpain2. Through truncation
research, we confirmed that the non-conserved C-terminal
region of HDAC3 is required for the interaction of calpain with
HDAC3, but the specific sequence remains to be illustrated.
Calpains are a family of calcium-dependent proteases, which are
profoundly and causally linked to post-ischemic insults (Bevers
and Neumar, 2008), and calpain inhibitors have been investigated
as potential therapeutics for cerebral ischemia (Koumura
et al., 2008). The sustained calcium overload in stroke led to
pathological activation of calpains, which resulted in extensive
degradation of structural proteins and enzymes and neuronal cell
death. The spectrin cleavages generated by calpains, SBDP150
and SBDP145, appeared 60 min after ischemia, and followed
by a second expansion between 24 and 48 h after reperfusion
(Neumar et al., 2001; Lin et al., 2013). These two steps of calpain
activation may indicate that the controlled activation of calpain
was induced at the beginning of ischemia, whereas sustained
calcium overload resulted in pathological hyper-activation of
calpains, which played predominant pathologic protease activity
in vulnerable neurons following ischemia (Zhang et al., 2002;
Liu et al., 2008). Regulated activation of calpain in the brain are
involved in synaptic function and memory formation, but the
mechanism underlying the controlled activation of calpain in PC
has not been illustrated. We propose that firstly, PC is not an
injurious stimulus, whereby transient signaling cascades may not
lead to loss of Ca2+ homeostasis and pronounced activation
of proteases. Secondly, other signaling pathways involved in
PC may regulate and stabilize the homeostasis of Ca2+. For
example, A1 adenosine receptors are reported to mediate
the protection against infarction afforded by PC (Liu et al.,
1991). And adenosine release from astrocytes down-regulated
the synaptic activity level in transient hypoxia by negatively
modulating the external or internal Ca2+ concentrations (Martín
et al., 2007).
Here, we demonstrated that HDAC3 inhibition increased the
resistance of the CNS to ischemic insult. Controlled activation
of calpains in PC was involved in the cleavage of HDAC3,
which reduced nuclear localization of HDAC3 and led to elevated
acetylation of H3K9 and initiation of neuroprotective genes.
Consistent with the role of HDAC inhibitors in neuroprotection,
this study illustrates the role of specific HDAC subtypes in
ischemic PC, and proposes new connections between PC and
epigenetic effectors.
ETHICS STATEMENT
The using of animals and experimental procedures were
performed following the rules of the Association for Assessment
and Accreditation of Laboratory Animal Care International and
approved by the Institutional Animal Care and Use Committee of
the Shanghai Institute of Material Medica, Chinese Academy of
Sciences. No endangered animals were applied in this research.
AUTHOR CONTRIBUTIONS
XY and LF designed experiments. XY and QW performed most
of the experiments. XY, QW, and LZ contributed to the animal
behavior studies. XY, QW, and LZ analyzed the data. XY and LF
wrote the paper.
ACKNOWLEDGMENTS
This work was supported by grants from “Key New Drug
Creation and Manufacturing Program” of the National Science
and Technology Major Project (2014ZX09102-001-05), and
the “Personalized Medicines—Molecular Signature-based Drug
Discovery and Development,” Strategic Priority Research
Program of the Chinese Academy of Sciences (XDA12040304).
All experiments were conducted in compliance with the ARRIVE
guidelines.
SUPPLEMENTARY MATERIAL
The Supplementary Material for this article can be found
online at: http://journal.frontiersin.org/article/10.3389/fnmol.
2016.00131/full#supplementary-material
Frontiers in Molecular Neuroscience | www.frontiersin.org 12 November 2016 | Volume 9 | Article 131
fnmol-09-00131 November 24, 2016 Time: 16:29 # 13
Yang et al. Inhibition of HDAC3 Mediates Ischemic Preconditioning
REFERENCES
Aune, S. E., Herr, D. J., Kutz, C. J., and Menick, D. R. (2015). Histone deacetylases
exert class-specific roles in conditioning the brain and heart against acute
ischemic injury. Front. Neurol. 6:145. doi: 10.3389/fneur.2015.00145
Bardai, F. H., and D’Mello, S. R. (2011). Selective toxicity by HDAC3 in neurons:
regulation by Akt and GSK3beta. J. Neurosci. 31, 1746–1751. doi: 10.1523/
JNEUROSCI.5704-10.2011
Bardai, F. H., Verma, P., Smith, C., Rawat, V., Wang, L., and D’Mello, S. R. (2013).
Disassociation of histone deacetylase-3 from normal huntingtin underlies
mutant huntingtin neurotoxicity. J. Neurosci. 33, 11833–11838. doi: 10.1523/
JNEUROSCI.5831-12.2013
Bates, E. A., Victor, M., Jones, A. K., Shi, Y., and Hart, A. C. (2006).
Differential contributions of Caenorhabditis elegans histone deacetylases to
huntingtin polyglutamine toxicity. J. Neurosci. 26, 2830–2838. doi: 10.1523/
JNEUROSCI.3344-05.2006
Bevers, M. B., and Neumar, R. W. (2008). Mechanistic role of calpains in
postischemic neurodegeneration. J. Cereb. Blood Flow Metab. 28, 655–673. doi:
10.1038/sj.jcbfm.9600595
Butler, R., and Bates, G. P. (2006). Histone deacetylase inhibitors as therapeutics for
polyglutamine disorders. Nat. Rev. Neurosci. 7, 784–796. doi: 10.1038/nrn1989
Choi, H. K., Choi, Y., Park, E. S., Park, S. Y., Lee, S. H., Seo, J., et al. (2015).
Programmed cell death 5 mediates HDAC3 decay to promote genotoxic stress
response. Nat. Commun. 6:7390. doi: 10.1038/ncomms8390
Chuang, D. M., Leng, Y., Marinova, Z., Kim, H. J., and Chiu, C. T. (2009). Multiple
roles of HDAC inhibition in neurodegenerative conditions. Trends Neurosci. 32,
591–601. doi: 10.1016/j.tins.2009.06.002
Dirnagl, U., Becker, K., and Meisel, A. (2009). Preconditioning and tolerance
against cerebral ischaemia: from experimental strategies to clinical use. Lancet
Neurol. 8, 398–412. doi: 10.1016/S1474-4422(09)70054-7
Dirnagl, U., Iadecola, C., and Moskowitz, M. A. (1999). Pathobiology of ischaemic
stroke: an integrated view. Trends Neurosci. 22, 391–397. doi: 10.1016/S0166-
2236(99)01401-0
Dirnagl, U., Simon, R. P., and Hallenbeck, J. M. (2003). Ischemic tolerance
and endogenous neuroprotection. Trends Neurosci. 26, 248–254. doi: 10.1016/
S0166-2236(03)00071-7
Escaffit, F., Vaute, O., Chevillard-Briet, M., Segui, B., Takami, Y., Nakayama, T.,
et al. (2007). Cleavage and cytoplasmic relocalization of histone deacetylase
3 are important for apoptosis progression. Mol. Cell. Biol. 27, 554–567. doi:
10.1128/MCB.00869-06
Fan, J., Alsarraf, O., Chou, C. J., Yates, P. W., Goodwin, N. C., Rice,
D. S., et al. (2016). Ischemic preconditioning, retinal neuroprotection and
histone deacetylase activities. Exp. Eye Res. 146, 269–275. doi: 10.1016/j.exer.
2016.03.026
Faraco, G., Pancani, T., Formentini, L., Mascagni, P., Fossati, G., Leoni, F., et al.
(2006). Pharmacological inhibition of histone deacetylases by suberoylanilide
hydroxamic acid specifically alters gene expression and reduces ischemic injury
in the mouse brain. Mol. Pharmacol. 70, 1876–1884. doi: 10.1124/mol.106.
027912
Feigin, V. L., Forouzanfar, M. H., Krishnamurthi, R., Mensah, G. A., Connor, M.,
Bennett, D. A., et al. (2014). Global and regional burden of stroke during 1990–
2010: findings from the Global Burden of Disease Study 2010. Lancet 383,
245–255. doi: 10.1016/S0140-6736(13)61953-4
Feng, D., Liu, T., Sun, Z., Bugge, A., Mullican, S. E., Alenghat, T., et al. (2011).
A circadian rhythm orchestrated by histone deacetylase 3 controls hepatic lipid
metabolism. Science 331, 1315–1319. doi: 10.1126/science.1198125
Finkel, T., and Holbrook, N. J. (2000). Oxidants, oxidative stress and the biology of
ageing. Nature 408, 239–247. doi: 10.1038/35041687
Fisher, M., and Saver, J. L. (2015). Future directions of acute ischaemic stroke
therapy. Lancet Neurol. 14, 758–767. doi: 10.1016/s1474-4422(15)00054-x
Gidday, J. M. (2006). Cerebral preconditioning and ischaemic tolerance. Nat. Rev.
Neurosci. 7, 437–448. doi: 10.1038/nrn1927
Hunter, A., Hatcher, J., Virley, D., Nelson, P., Irving, E., Hadingham, S.,
et al. (2000). Functional assessments in mice and rats after focal stroke.
Neuropharmacology 39, 806–816. doi: 10.1016/S0028-3908(99)00262-2
Johnston, S. C., Mendis, S., and Mathers, C. D. (2009). Global variation in stroke
burden and mortality: estimates from monitoring, surveillance, and modelling.
Lancet Neurol. 8, 345–354. doi: 10.1016/S1474-4422(09)70023-7
Karagianni, P., and Wong, J. (2007). HDAC3: taking the SMRT-N-CoRrect road to
repression. Oncogene 26, 5439–5449. doi: 10.1038/sj.onc.1210612
Kim, H. J., Rowe, M., Ren, M., Hong, J. S., Chen, P. S., and Chuang, D. M. (2007).
Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective
effects in a rat permanent ischemic model of stroke: multiple mechanisms
of action. J. Pharmacol. Exp. Ther. 321, 892–901. doi: 10.1124/jpet.107.
120188
Koronowski, K. B., Dave, K. R., Saul, I., Camarena, V., Thompson, J. W., Neumann,
J. T., et al. (2015). Resveratrol preconditioning induces a novel extended
window of ischemic tolerance in the mouse brain. Stroke 46, 2293–2298. doi:
10.1161/STROKEAHA.115.009876
Koumura, A., Nonaka, Y., Hyakkoku, K., Oka, T., Shimazawa, M., Hozumi, I., et al.
(2008). A novel calpain inhibitor,((1S)-1 ((((1S)-1-benzyl-3-cyclopropylamino-
2, 3-di-oxopropyl) amino) carbonyl)-3-methylbutyl) carbamic acid 5-methoxy-
3-oxapentyl ester, protects neuronal cells from cerebral ischemia-induced
damage in mice. Neuroscience 157, 309–318. doi: 10.1016/j.neuroscience.
2008.09.007
Langley, B., Brochier, C., and Rivieccio, M. A. (2009). Targeting histone
deacetylases as a multifaceted approach to treat the diverse outcomes of stroke.
Stroke 40, 2899–2905. doi: 10.1161/STROKEAHA.108.540229
Lin, Y., Zhang, J.-C., Fu, J., Chen, F., Wang, J., Wu, Z.-L., et al. (2013). Hyperforin
attenuates brain damage induced by transient middle cerebral artery occlusion
(MCAO) in rats via inhibition of TRPC6 channels degradation. J. Cereb. Blood
Flow Metab. 33, 253–262. doi: 10.1038/jcbfm.2012.164
Liu, G., Thornton, J., Van Winkle, D., Stanley, A., Olsson, R., and Downey, J. (1991).
Protection against infarction afforded by preconditioning is mediated by A1
adenosine receptors in rabbit heart. Circulation 84, 350–356. doi: 10.1161/01.
CIR.84.1.350
Liu, J., Liu, M. C., and Wang, K. (2008). Calpain in the CNS: from synaptic function
to neurotoxicity. Sci. Signal. 1:re1. doi: 10.1126/stke.114re1
Longa, E. Z., Weinstein, P. R., Carlson, S., and Cummins, R. (1989). Reversible
middle cerebral artery occlusion without craniectomy in rats. Stroke 20, 84–91.
doi: 10.1161/01.STR.20.1.84
Malvaez, M., McQuown, S. C., Rogge, G. A., Astarabadi, M., Jacques, V.,
Carreiro, S., et al. (2013). HDAC3-selective inhibitor enhances extinction of
cocaine-seeking behavior in a persistent manner. Proc. Natl. Acad. Sci. U.S.A.
110, 2647–2652. doi: 10.1073/pnas.1213364110
Martín, E. D., Fernández, M., Perea, G., Pascual, O., Haydon, P. G., Araque, A.,
et al. (2007). Adenosine released by astrocytes contributes to hypoxia-induced
modulation of synaptic transmission. Glia 55, 36–45. doi: 10.1002/glia.20431
Masada, T., Hua, Y., Xi, G., Ennis, S. R., and Keep, R. F. (2001).
Attenuation of ischemic brain edema and cerebrovascular injury after ischemic
preconditioning in the rat. J. Cereb. Blood Flow Metab. 21, 22–33. doi: 10.1097/
00004647-200101000-00004
Moretti, A., Ferrari, F., and Villa, R. F. (2015). Pharmacological therapy of acute
ischaemic stroke: achievements and problems. Pharmacol. Ther. 153, 79–89.
doi: 10.1016/j.pharmthera.2015.06.004
Moskowitz, M. A., Lo, E. H., and Iadecola, C. (2010). The science of stroke:
mechanisms in search of treatments. Neuron 67, 181–198. doi: 10.1016/j.
neuron.2010.07.002
Neumar, R. W., Meng, F. H., Mills, A. M., Xu, Y. A., Zhang, C., Welsh, F. A., et al.
(2001). Calpain activity in the rat brain after transient forebrain ischemia. Exp.
Neurol. 170, 27–35. doi: 10.1006/exnr.2001.7708
Park, H. A., Licznerski, P., Alavian, K. N., Shanabrough, M., and Jonas, E. A. (2015).
Bcl-xL is necessary for neurite outgrowth in hippocampal neurons. Antioxid.
Redox. Signal. 22, 93–108. doi: 10.1089/ars.2013.5570
Prass, K., Scharff, A., Ruscher, K., Lowl, D., Muselmann, C., Victorov, I.,
et al. (2003). Hypoxia-induced stroke tolerance in the mouse is mediated
by erythropoietin. Stroke 34, 1981–1986. doi: 10.1161/01.STR.0000080381.
76409.B2
Raval, A. P., Dave, K. R., and Perez-Pinzon, M. A. (2006). Resveratrol mimics
ischemic preconditioning in the brain. J. Cereb. Blood Flow Metab. 26,
1141–1147. doi: 10.1038/sj.jcbfm.9600262
Ren, M., Leng, Y., Jeong, M., Leeds, P. R., and Chuang, D. M. (2004). Valproic
acid reduces brain damage induced by transient focal cerebral ischemia
in rats: potential roles of histone deacetylase inhibition and heat shock
protein induction. J. Neurochem. 89, 1358–1367. doi: 10.1111/j.1471-4159.2004.
02406.x
Frontiers in Molecular Neuroscience | www.frontiersin.org 13 November 2016 | Volume 9 | Article 131
fnmol-09-00131 November 24, 2016 Time: 16:29 # 14
Yang et al. Inhibition of HDAC3 Mediates Ischemic Preconditioning
Samantaray, S., Knaryan, V. H., Shields, D. C., Cox, A. A., Haque, A., and Banik,
N. L. (2015). Inhibition of calpain activation protects MPTP-Induced nigral
and spinal cord neurodegeneration, reduces inflammation, and improves gait
dynamics in mice. Mol. Neurobiol. 52, 1054–1066. doi: 10.1007/s12035-015-
9255-6
Schmitt, H. M., Pelzel, H. R., Schlamp, C. L., and Nickells, R. W. (2014). Histone
deacetylase 3 (HDAC3) plays an important role in retinal ganglion cell death
after acute optic nerve injury. Mol. Neurodegen 9:1. doi: 10.1186/1750-1326-
9-39
Stenzel-Poore, M. P., Stevens, S. L., King, J. S., and Simon, R. P. (2007).
Preconditioning reprograms the response to ischemic injury and primes the
emergence of unique endogenous neuroprotective phenotypes: a speculative
synthesis. Stroke 38 2(Suppl.), 680–685. doi: 10.1161/01.STR.0000251444.
56487.4c
Stenzel-Poore, M. P., Stevens, S. L., Xiong, Z., Lessov, N. S., Harrington, C. A.,
Mori, M., et al. (2003). Effect of ischaemic preconditioning on genomic
response to cerebral ischaemia: similarity to neuroprotective strategies in
hibernation and hypoxia-tolerant states. Lancet 362, 1028–1037. doi: 10.1016/
S0140-6736(03)14412-1
Stetler, R. A., Leak, R. K., Gan, Y., Li, P., Zhang, F., Hu, X., et al.
(2014). Preconditioning provides neuroprotection in models of CNS disease:
paradigms and clinical significance. Prog. Neurobiol. 114, 58–83. doi: 10.1016/j.
pneurobio.2013.11.005
Stevens, S. L., Vartanian, K. B., and Stenzel-Poore, M. P. (2014). Reprogramming
the response to stroke by preconditioning. Stroke 45, 2527–2531. doi: 10.1161/
STROKEAHA.114.002879
Tang, Y., Pacary, E., Freret, T., Divoux, D., Petit, E., Schumann-Bard, P.,
et al. (2006). Effect of hypoxic preconditioning on brain genomic response
before and following ischemia in the adult mouse: identification of potential
neuroprotective candidates for stroke. Neurobiol. Dis. 21, 18–28. doi: 10.1016/j.
nbd.2005.06.002
Thompson, J. W., Dave, K. R., Young, J. I., and Perez-Pinzon, M. A. (2013).
Ischemic preconditioning alters the epigenetic profile of the brain from
ischemic intolerance to ischemic tolerance. Neurotherapeutics 10, 789–797. doi:
10.1007/s13311-013-0202-9
Wang, B., Zhu, X., Kim, Y., Li, J., Huang, S., Saleem, S., et al.
(2012a). Histone deacetylase inhibition activates transcription
factor Nrf2 and protects against cerebral ischemic damage. Free
Radic. Biol. Med. 52, 928–936. doi: 10.1016/j.freeradbiomed.2011.
12.006
Wang, Z., Tsai, L. K., Munasinghe, J., Leng, Y., Fessler, E. B., Chibane, F., et al.
(2012b). Chronic valproate treatment enhances postischemic angiogenesis and
promotes functional recovery in a rat model of ischemic stroke. Stroke 43,
2430–2436. doi: 10.1161/STROKEAHA.112.652545
Xie, K. Q., Zhang, L. M., Cao, Y., Zhu, J., and Feng, L. Y. (2009). Adenosine
A(1) receptor-mediated transactivation of the EGF receptor produces a
neuroprotective effect on cortical neurons in vitro. Acta Pharmacol. Sin. 30,
889–898. doi: 10.1038/aps.2009.80
Yang, W. M., Tsai, S. C., Wen, Y. D., Fejer, G., and Seto, E. (2002). Functional
domains of histone deacetylase-3. J. Biol. Chem. 277, 9447–9454. doi: 10.1074/
jbc.M105993200
Yang, X. J., and Seto, E. (2008). The Rpd3/Hda1 family of lysine deacetylases:
from bacteria and yeast to mice and men. Nat. Rev. Mol. Cell Biol. 9, 206–218.
doi: 10.1038/nrm2346
Yildirim, F., Gertz, K., Kronenberg, G., Harms, C., Fink, K. B., Meisel, A., et al.
(2008). Inhibition of histone deacetylation protects wildtype but not gelsolin-
deficient mice from ischemic brain injury. Exp. Neurol. 210, 531–542. doi:
10.1016/j.expneurol.2007.11.031
Yildirim, F., Ji, S., Kronenberg, G., Barco, A., Olivares, R., Benito, E., et al. (2014).
Histone acetylation and CREB binding protein are required for neuronal
resistance against ischemic injury. PLoS ONE 9:e95465. doi: 10.1371/journal.
pone.0095465
Zhan, X., Ander, B. P., Liao, I. H., Hansen, J. E., Kim, C., Clements, D., et al. (2010).
Recombinant Fv-Hsp70 protein mediates neuroprotection after focal cerebral
ischemia in rats. Stroke 41, 538–543. doi: 10.1161/STROKEAHA.109.572537
Zhang, C., Siman, R., Xu, Y. A., Mills, A. M., Frederick, J. R., and Neumar, R. W.
(2002). Comparison of calpain and caspase activities in the adult rat brain after
transient forebrain ischemia. Neurobiol. Dis. 10, 289–305. doi: 10.1006/nbdi.
2002.0526
Conflict of Interest Statement: The authors declare that the research was
conducted in the absence of any commercial or financial relationships that could
be construed as a potential conflict of interest.
Copyright © 2016 Yang, Wu, Zhang and Feng. This is an open-access article
distributed under the terms of the Creative Commons Attribution License (CC BY).
The use, distribution or reproduction in other forums is permitted, provided the
original author(s) or licensor are credited and that the original publication in this
journal is cited, in accordance with accepted academic practice. No use, distribution
or reproduction is permitted which does not comply with these terms.
Frontiers in Molecular Neuroscience | www.frontiersin.org 14 November 2016 | Volume 9 | Article 131
